Clinical Trial Update: Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B [Phase 3]

View source ↗

Summary

Phase 3 study of BIIB029, a recombinant coagulation factor IX Fc fusion protein, in previously treated pediatric participants with Hemophilia B has completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BIIB029

Snippet

Sponsor: Bioverativ Therapeutics Inc. | Conditions: Hemophilia B | Phase 3 | Status: COMPLETED | Results posted: 2015-06-18